(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

(108-20) A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

(127-21) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(130-21) A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations

(131-21) Tumor-Agnostic precision immuno-oncology and somatic targeting rational for you (tapistry) Phase II platform trial

(152-17) Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

(160-21) A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors

(162-20) A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer

(163-20) A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803 in Combination with Current Standard of Care vs Standard of Care as First-Line Treatment for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

(187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

(188-20) A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

(195-20) Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

(196-21) A Phase 1 b/2 study of repotrectinib in combination with other anticancer therapies for the treatment of subjects with KRAS-Mutant advanced solid tumor (TRIDENT-2)

(205-19) Study to Assess AFM24 in Advanced Solid Cancers

(209-20) First-In-Human Dose-Escalation Study of SRP1002 in Patients with Advanced-Stage Solid Tumors

(213-20) A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

(214-17) A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

(221-19) Study of GNX102 in Patients With Advanced Solid Tumors

(231-20) A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

(243-20) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(220-21) A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

Certain clinical trials may not be listed on To learn more about these or other clinical trials, please call 949-764-5543